Rhenium (186Re) obisbemeda

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameRhenium (186Re) obisbemeda
Drug Alias NameRhenium-186 Nanoliposome铼-186纳米脂质体Rhenium Re186 ObisbemedaReSPECT-LM186-Rheneium nanoliposome +[10] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Rhenium > 186Re
Mechanisms of ActionIonising radiation emitters
TargetsNot applicable
Therapy Area/IndicationsHigh-Grade GliomaMeningeal NeoplasmsEpendymoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPlus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCancer Prevention Research Institute Of TexasPlus Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHigh-Grade GliomaMeningeal NeoplasmsEpendymoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A